

# C Michael Gibson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4721299/publications.pdf>

Version: 2024-02-01

575  
papers

64,988  
citations

1231

110  
h-index

890

242  
g-index

690  
all docs

690  
docs citations

690  
times ranked

37471  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2007, 357, 2001-2015.	13.9	5,933
2	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
3	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
4	Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. <i>New England Journal of Medicine</i> , 2001, 344, 1879-1887.	13.9	1,918
5	Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. <i>New England Journal of Medicine</i> , 2005, 352, 1179-1189.	13.9	1,739
6	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
7	TIMI Frame Count. <i>Circulation</i> , 1996, 93, 879-888.	1.6	1,556
8	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016, 375, 2423-2434.	13.9	1,265
9	Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 723-731.	6.3	981
10	The VIVA Trial. <i>Circulation</i> , 2003, 107, 1359-1365.	1.6	964
11	Relationship of TIMI Myocardial Perfusion Grade to Mortality After Administration of Thrombolytic Drugs. <i>Circulation</i> , 2000, 101, 125-130.	1.6	808
12	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2014, 130, 484-495.	1.6	783
13	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	13.9	695
14	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
15	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
16	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
17	Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 1760-1763.	1.6	680
18	Abciximab Facilitates the Rate and Extent of Thrombolysis. <i>Circulation</i> , 1999, 99, 2720-2732.	1.6	661

#	ARTICLE	IF	CITATIONS
19	Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 294, 1224.	3.8	644
20	Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes. Circulation, 2005, 111, 2042-2049.	1.6	613
21	Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2008, 51, 1369-1374.	1.2	604
22	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	13.9	593
23	Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 294, 3108.	3.8	587
24	Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine, 2009, 361, 2330-2341.	13.9	560
25	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	6.3	537
26	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine, 2009, 361, 2318-2329.	13.9	533
27	Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 2096.	3.8	525
28	Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction. Circulation, 2006, 114, 2019-2025.	1.6	472
29	Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 307, 1817.	3.8	471
30	Previous Angina Alters In-Hospital Outcome in TIMI 4. Circulation, 1995, 91, 37-45.	1.6	448
31	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	1.2	445
32	Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. Circulation, 2001, 103, 2550-2554.	1.6	440
33	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
34	Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation, 2003, 107, 690-695.	1.6	412
35	Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2009, 54, 220-228.	1.2	399
36	Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded. Annals of Internal Medicine, 2005, 142, 786.	2.0	396

#	ARTICLE	IF	CITATIONS
37	Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non-ST-elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1264-1272.	1.2	393
38	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
39	Relationship Between TIMI Frame Count and Clinical Outcomes After Thrombolytic Administration. <i>Circulation</i> , 1999, 99, 1945-1950.	1.6	368
40	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
41	Soluble CD40L. <i>Circulation</i> , 2003, 108, 1049-1052.	1.6	367
42	Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction. <i>Circulation</i> , 2002, 105, 1909-1913.	1.6	361
43	Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery. <i>New England Journal of Medicine</i> , 2009, 361, 235-244.	13.9	356
44	Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. <i>American Heart Journal</i> , 2008, 156, 1026-1034.	1.2	350
45	Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction. <i>Circulation</i> , 2000, 102, 2329-2334.	1.6	344
46	Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2011, 124, 40-47.	1.6	343
47	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
48	TNK-Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. <i>Circulation</i> , 1998, 98, 2805-2814.	1.6	307
49	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 254.	3.8	299
50	Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). <i>American Heart Journal</i> , 2006, 152, 627-635.	1.2	290
51	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet, The</i> , 2013, 382, 1981-1992.	6.3	286
52	Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2008, 1, 184-191.	1.6	269
53	Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2000, 101, 239-243.	1.6	267
54	Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1761-1768.	1.2	250

#	ARTICLE	IF	CITATIONS
55	Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1535-1543.	1.2	247
56	Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. <i>American Heart Journal</i> , 2008, 156, 1035-1044.	1.2	240
57	Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2002, 105, 1642-1649.	1.6	228
58	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 857-867.	1.1	223
59	Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. <i>American Heart Journal</i> , 2008, 156, 1045-1055.	1.2	216
60	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1034.	1.2	211
61	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
62	TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction. <i>Circulation</i> , 1997, 95, 351-356.	1.6	209
63	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
64	Relation of Neutrophil/Lymphocyte Ratio to Coronary Flow to In-Hospital Major Adverse Cardiac Events in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 110, 621-627.	0.7	202
65	Controlled trial of fish oil for regression of human coronary atherosclerosis. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1492-1498.	1.2	200
66	Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2008, 117, 886-896.	1.6	200
67	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	3.0	198
68	Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction. <i>Circulation</i> , 2001, 104, 2778-2783.	1.6	197
69	B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 335-339.	1.2	196
70	Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2120-7.	3.8	187
71	Distal Embolization of Thrombus in Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2006, 119, e1-e2.	0.6	184
72	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2014, 130, 1445-1451.	1.6	181

#	ARTICLE	IF	CITATIONS
73	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
74	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	18.1	179
75	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , The, 2017, 389, 1799-1808.	6.3	174
76	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007, 28, 2077-2086.	1.0	172
77	Phase II Safety and Clinical Comparison With Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 469-477.	1.2	172
78	Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. <i>American Heart Journal</i> , 2006, 152, 641-647.	1.2	171
79	Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 109, 580-586.	1.6	169
80	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. <i>European Heart Journal</i> , 2011, 32, 2541-2554.	1.0	165
81	Meta-analysis of corticosteroid treatment in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 91, 1055-1059.	0.7	160
82	Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. <i>Journal of the American College of Cardiology</i> , 2003, 42, 7-16.	1.2	160
83	Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. <i>European Heart Journal</i> , 2009, 30, 1195-1202.	1.0	157
84	Coronary and Myocardial Angiography. <i>Circulation</i> , 2004, 109, 3096-3105.	1.6	155
85	Benefit of Transferring ST-Segment Elevation Myocardial Infarction Patients for Percutaneous Coronary Intervention Compared With Administration of Onsite Fibrinolytic Declines as Delays Increase. <i>Circulation</i> , 2011, 124, 2512-2521.	1.6	155
86	U-Shaped Relationship of Blood Glucose With Adverse Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 178-180.	1.2	152
87	Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. <i>Coronary Artery Disease</i> , 2011, 22, 138-144.	0.3	149
88	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1918-1930.	1.6	148
89	Predictors of door-to-balloon delay in primary angioplasty. <i>American Journal of Cardiology</i> , 2002, 89, 1156-1161.	0.7	147
90	Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. <i>European Heart Journal</i> , 2007, 28, 949-960.	1.0	147

#	ARTICLE	IF	CITATIONS
91	TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association With Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging. <i>Circulation</i> , 2002, 105, 282-285.	1.6	145
92	Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2012, 125, 749-756.	1.6	143
93	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). <i>American Heart Journal</i> , 2015, 169, 472-478.e5.	1.2	140
94	Spectrum and Clinical Significance of Systolic Function and Myocardial Fibrosis Assessed by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 106, 261-267.	0.7	139
95	Saphenous vein grafts in contemporary coronary artery bypass graft surgery. <i>Nature Reviews Cardiology</i> , 2020, 17, 155-169.	6.1	139
96	Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 441-447.	1.3	138
97	Hypertrophic Cardiomyopathy: Quantification of Late Gadolinium Enhancement with Contrast-enhanced Cardiovascular MR Imaging. <i>Radiology</i> , 2011, 258, 128-133.	3.6	137
98	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500.	1.6	132
99	Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>Circulation</i> , 2003, 108, 951-957.	1.6	131
100	Significance of Papillary Muscle Abnormalities Identified by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2008, 101, 668-673.	0.7	130
101	Diagnostic and Prognostic Utility of Brain Natriuretic Peptide in Subjects Admitted to the ICU With Hypoxic Respiratory Failure Due to Noncardiogenic and Cardiogenic Pulmonary Edema. <i>Chest</i> , 2007, 131, 964-971.	0.4	128
102	Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. <i>European Heart Journal</i> , 2004, 25, 1998-2005.	1.0	124
103	Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion. <i>Circulation</i> , 2002, 106, 202-207.	1.6	122
104	A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2364-2373.	1.2	122
105	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	1.2	122
106	Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. <i>American Heart Journal</i> , 2009, 157, 716-723.	1.2	121
107	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
108	Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2013, 62, 449-457.	1.2	118

#	ARTICLE	IF	CITATIONS
109	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020, 226, 49-59.	1.2	118
110	Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality Among Patients With Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1781-1786.	1.2	117
111	Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery. <i>Circulation</i> , 2011, 124, 280-288.	1.6	116
112	Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1417-1424.	1.2	113
113	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2016, 37, 1296.1-1303.	1.0	112
114	Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2374-2379.	1.2	110
115	Coronary Artery Bypass Graft Failure After On-Pump and Off-Pump Coronary Artery Bypass: Findings From PREVENT IV. <i>Annals of Thoracic Surgery</i> , 2008, 85, 494-500.	0.7	110
116	Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2238-2246.	1.2	109
117	Delayed-Enhancement Cardiovascular Magnetic Resonance Coronary Artery Wall Imaging. <i>Journal of the American College of Cardiology</i> , 2007, 50, 441-447.	1.2	108
118	Prognostic Value of Uric Acid in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 486-491.	0.7	108
119	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	1.2	108
120	Association of Elevated B-Type Natriuretic Peptide Levels With Angiographic Findings Among Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 564-568.	1.2	107
121	A Reevaluation of the Costs of Heart Failure and Its Implications for Allocation of Health Resources in the United States. <i>Clinical Cardiology</i> , 2014, 37, 312-321.	0.7	107
122	REDUCE-IT USA. <i>Circulation</i> , 2020, 141, 367-375.	1.6	104
123	Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2290-2295.	1.2	103
124	Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function. <i>Circulation</i> , 2010, 121, 784-791.	1.6	100
125	Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients. <i>American Heart Journal</i> , 1994, 128, 252-255.	1.2	98
126	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65.	0.7	94



#	ARTICLE	IF	CITATIONS
127	Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1251-1260.	1.2	93
128	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
129	Significance of False Negative Electrocardiograms in Preparticipation Screening of Athletes for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2012, 110, 1027-1032.	0.7	92
130	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	1.2	92
131	Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 93, 532-536.	0.7	91
132	Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. <i>American Heart Journal</i> , 2006, 152, 668-675.	1.2	91
133	Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012, 163, 182-190.e4.	1.2	89
134	Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1853-1859.	1.2	89
135	Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. <i>American Heart Journal</i> , 2011, 161, 815-821.e6.	1.2	88
136	Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. <i>Journal of the American College of Cardiology</i> , 2013, 62, 286-290.	1.2	88
137	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
138	Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery. <i>Annals of Thoracic Surgery</i> , 2007, 83, 993-1001.	0.7	86
139	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017, 135, 323-333.	1.6	86
140	The Early Glycoprotein IIb/IIIa Inhibition in Non-“ST-Segment Elevation Acute Coronary Syndrome (EARLY) Tj ETQq0 0 0 rgBT /Overlock front-loaded eptifibatide in the treatment of patients with non-“ST-segment elevation acute coronary syndrome—Study design and rationale. <i>American Heart Journal</i> , 2005, 149, 994-1002.	1.2	85
141	Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. <i>Atherosclerosis</i> , 2009, 207, 181-185.	0.4	85
142	A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y <sub>12</sub> Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 336-346.	1.4	81
143	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014, 167, 335-341.	1.2	81
144	Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 806-811.	1.1	79

#	ARTICLE	IF	CITATIONS
145	Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 715-723.	1.2	79
146	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. <i>European Heart Journal</i> , 2022, 43, 959-967.	1.0	79
147	Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1063-1072.	3.0	76
148	d-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 55-59.	1.0	75
149	Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non-â€œST-Segmentâ€œ Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2012, 126, 41-49.	1.6	74
150	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. <i>JAMA Surgery</i> , 2014, 149, 798.	2.2	74
151	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. <i>American Heart Journal</i> , 2015, 170, 1061-1069.	1.2	74
152	High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction. <i>Circulation</i> , 2000, 101, 2690-2695.	1.6	73
153	Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk score for unstable angina pectoris and non-â€œST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , 2002, 90, 303-305.	0.7	72
154	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of élinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). <i>American Heart Journal</i> , 2010, 160, 65-72.	1.2	72
155	Rationale and design of the Cangrelor versus standard therapy to achIEve optimal Management of Platelet InhibitiON PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	1.2	72
156	Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2013, 165, 509-514.e7.	1.2	72
157	Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. <i>American Heart Journal</i> , 2004, 148, 336-340.	1.2	71
158	NRMI and current treatment patterns for ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2004, 148, S29-S33.	1.2	71
159	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	3.0	71
160	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	6.1	71
161	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
162	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes. <i>Circulation</i> , 2016, 133, 131-138.	1.6	70

#	ARTICLE	IF	CITATIONS
163	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	1.2	69
164	Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. <i>Journal of Invasive Cardiology</i> , 2002, 14, 299-302.	0.4	68
165	Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. <i>American Heart Journal</i> , 2007, 154, 702-709.	1.2	67
166	Relation of red cell distribution width with the presence, severity, and complexity of coronary artery disease. <i>Coronary Artery Disease</i> , 2012, 23, 51-56.	0.3	67
167	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013, 167, 1772-1782.	0.8	67
168	Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the Tj ETQq0 0 0 rgBT7Overlock 10 Tf 50)	0.7	67
169	Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection. <i>American Journal of Cardiology</i> , 2019, 123, 1783-1787.	0.7	66
170	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	1.2	66
171	Association of Blood Glucose With Angiographic and Clinical Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction (from the CLARITY-TIMI-28 Study). <i>American Journal of Cardiology</i> , 2008, 101, 303-307.	0.7	64
172	Predictive Value of Admission Platelet Volume Indices for In-hospital Major Adverse Cardiovascular Events in Acute ST-Segment Elevation Myocardial Infarction. <i>Angiology</i> , 2015, 66, 155-162.	0.8	63
173	Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 92, 913-918.	0.7	62
174	Angiographic predictors of reocclusion after thrombolysis: Results from the thrombolysis in myocardial infarction (TIMI) 4 trial. <i>Journal of the American College of Cardiology</i> , 1995, 25, 582-589.	1.2	61
175	Prevalence, Consequences, and Implications for Clinical Trials of Unrecognized Myocardial Infarction. <i>American Journal of Cardiology</i> , 2013, 111, 914-918.	0.7	61
176	Significance of left ventricular apicalâ€“basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2706-2713.	1.0	61
177	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.	1.6	61
178	The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 48, 37-42.	1.2	60
179	Characterization of Microvascular Dysfunction After Acute Myocardial Infarction by Cardiovascular Magnetic Resonance First-Pass Perfusion and Late Gadolinium Enhancement Imaging. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2006, 8, 831-837.	1.6	60
180	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60

#	ARTICLE	IF	CITATIONS
181	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60
182	Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. <i>American Heart Journal</i> , 2005, 149, 846-850.	1.2	59
183	Intermediate-Signal-Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 78-85.	1.3	59
184	Intralesional Abciximab and Thrombus Aspiration in Patients With Large Anterior Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 527-534.	1.4	59
185	Impact of Perioperative Myocardial Infarction on Angiographic and Clinical Outcomes Following Coronary Artery Bypass Grafting (from Project of Ex-vivo Vein graft Engineering via Transfection) <i>Tj ETQq1 1 0.784314 rgBT #8 Overloc</i>	1.4	58
186	Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. <i>American Heart Journal</i> , 2003, 145, 109-117.	1.2	57
187	Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. <i>European Heart Journal</i> , 2006, 27, 2310-2316.	1.0	57
188	Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 37-45.	0.4	57
189	Impact of Delay to Reperfusion on Reperfusion Success, Infarct Size, and Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 733-740.	1.1	56
190	Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. <i>PLoS ONE</i> , 2021, 16, e0251963.	1.1	56
191	Influence of Race on Death and Ischemic Complications in Patients With Non-ST-Elevation Acute Coronary Syndromes Despite Modern, Protocol-Guided Treatment. <i>Circulation</i> , 2005, 111, 1217-1224.	1.6	55
192	Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome. <i>European Heart Journal</i> , 2005, 26, 440-446.	1.0	54
193	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357.	1.1	54
194	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022.	1.2	54
195	The smoker's paradox: insights from the angiographic substudies of the TIMI trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 13, 133-139.	1.0	53
196	The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2002, 40, 238-244.	1.2	52
197	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e017212.	1.6	52
198	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. <i>American Heart Journal</i> , 2005, 149, 227-233.	1.2	51

#	ARTICLE	IF	CITATIONS
199	Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 110, 679-684.	1.6	50
200	Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. <i>European Heart Journal</i> , 2007, 28, 806-813.	1.0	50
201	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019, 94, 21-28.	2.0	50
202	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
203	Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. <i>American Journal of Cardiology</i> , 2004, 93, 1362-1367.	0.7	49
204	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018, 39, 4112-4121.	1.0	49
205	The PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial. <i>American Heart Journal</i> , 2005, 150, 643-649.	1.2	48
206	Does Serum Bilirubin Level on Admission Predict TIMI Flow Grade and In-Hospital MACE in Patients With STEMI Undergoing Primary PCI. <i>Angiology</i> , 2014, 65, 198-204.	0.8	48
207	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 185, 93-100.	1.2	48
208	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2046-2052.	1.8	48
209	Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2002, 90, 631-633.	0.7	47
210	Myonecrosis following stent placement: Association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 472-476.	0.7	47
211	Association Between Blood Glucose and Long-Term Mortality in Patients With Acute Coronary Syndromes in the OPUS-TIMI 16 Trial. <i>American Journal of Cardiology</i> , 2006, 97, 1573-1577.	0.7	47
212	Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 316-328.	1.0	47
213	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	1.2	47
214	Outcome in Patients Transferred for Percutaneous Coronary Intervention (A National Registry of Patients Undergoing Percutaneous Coronary Intervention). <i>Journal of the American College of Cardiology</i> , 2010, 55, 46-50.	0.7	46
215	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46
216	Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. <i>European Heart Journal</i> , 2008, 29, 984-991.	1.0	45

#	ARTICLE	IF	CITATIONS
217	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
218	A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 799-803.	1.2	43
219	Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 980-987.	1.2	43
220	Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy. <i>American Heart Journal</i> , 2002, 143, 106-110.	1.2	42
221	Distance from the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding the Potential Prevention of Proximal Plaque Rupture. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 15, 189-196.	1.0	42
222	Atherosclerotic Risk Factors and Their Association With Hospital Mortality Among Patients With First Myocardial Infarction (from the National Registry of Myocardial Infarction). <i>American Journal of Cardiology</i> , 2012, 110, 1256-1261.	0.7	42
223	Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 718-724.	1.1	42
224	The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. <i>American Journal of Cardiology</i> , 1995, 76, 78C-85C.	0.7	40
225	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40
226	Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 57, 125-134.	0.7	39
227	Initial Clinical Results Using Intracardiac Electrogram Monitoring to Detect and Alert Patients During Coronary Plaque Rupture and Ischemia. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1089-1098.	1.2	39
228	Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 193-200.	0.2	39
229	Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. <i>Coronary Artery Disease</i> , 2011, 22, 131-137.	0.3	39
230	Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. <i>Journal of the American College of Cardiology</i> , 2013, 62, 242-251.	1.2	39
231	A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. <i>American Heart Journal</i> , 2015, 170, 929-937.	1.2	39
232	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855.	1.6	39
233	Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors: insights from the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 342-346.	1.0	38
234	Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: A systematic review. <i>American Heart Journal</i> , 2013, 165, 451-467.	1.2	38

#	ARTICLE	IF	CITATIONS
235	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	1.1	38
236	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1461-1469.	1.1	37
237	Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2022, 347, 89-96.	0.8	37
238	Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. <i>American Journal of Cardiology</i> , 1993, 71, 766-772.	0.7	36
239	Has My Patient Achieved Adequate Myocardial Reperfusion?. <i>Circulation</i> , 2003, 108, 504-507.	1.6	36
240	Rationale and design of the INFUSE-AMI study: A 2x2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2011, 161, 478-486.e7.	1.2	36
241	Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from the Tj ETQq1 1 0,784314 rgBT /Overle	0.7	36
242	A Living Systematic Review of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants. <i>JAMA Pediatrics</i> , 2015, 169, 788.	3.3	36
243	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 127.	3.0	36
244	Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 1-9.	1.0	36
245	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671.	1.2	36
246	Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010, 31, 2103-2110.	1.0	35
247	Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 671-683.	1.1	35
248	Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial). <i>American Journal of Cardiology</i> , 2014, 113, 1457-1460.	0.7	35
249	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 424-433.	1.1	35
250	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	1.2	35
251	Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting. <i>Annals of Internal Medicine</i> , 1999, 130, 841.	2.0	33
252	Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. <i>American Heart Journal</i> , 2002, 144, 130-135.	1.2	33

#	ARTICLE	IF	CITATIONS
253	Association between Thrombolysis in Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: Observations from the Randomized Trial to Evaluate the Relative PROTECTION against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic Agentsâ€“Thrombolysis in Myocardial Infarction 30 (PROTECT-TIMI 30). American Heart Journal, 2006, 152, 156-165.	1.2	33
254	Comparison of Effects of Bare Metal Versus Drug-Eluting Stent Implantation on Biomarker Levels Following Percutaneous Coronary Intervention for Nonâ€“ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2006, 97, 1473-1477.	0.7	33
255	Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. American Journal of Cardiology, 2004, 94, 1406-1410.	0.7	32
256	Outcomes Among Patients With ST-Segmentâ€“Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 574-582.	0.9	32
257	Association of TIMI Myocardial Perfusion Grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis, 2009, 27, 123-129.	1.0	32
258	Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)â€“Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy. American Heart Journal, 2009, 158, e21-e26.	1.2	32
259	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	32
260	Spontaneous coronary artery dissection and its association with takotsubo syndrome: Novel insights from a tertiary center registry. Catheterization and Cardiovascular Interventions, 2020, 95, 485-491.	0.7	32
261	Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. European Heart Journal, 2004, 25, 1702-1710.	1.0	31
262	Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Journal of Cardiology, 2009, 103, 1056-1060.	0.7	31
263	Thrombolytics and Myocardial Infarction. Cardiovascular Therapeutics, 2012, 30, e81-8.	1.1	31
264	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. Circulation, 2016, 134, 723-733.	1.6	31
265	Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 321-323.	1.2	30
266	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
267	Time is muscle in primary PCI: the strength of the evidence grows. European Heart Journal, 2004, 25, 1001-1002.	1.0	29
268	Vascular endothelial growth factors in pulmonary edema: an update. Journal of Thrombosis and Thrombolysis, 2008, 25, 259-264.	1.0	29
269	Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: Results of a multicenter case-control study with 145 thrombosis events. American Heart Journal, 2008, 155, 654-660.	1.2	29
270	Intracoronary bolusâ€“only compared with intravenous bolus plus infusion of tirofiban application in patients with STâ€“elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2012, 79, 59-67.	0.7	29



#	ARTICLE	IF	CITATIONS
271	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016, 174, 120-128.	1.2	29
272	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018, 131, 972.e1-972.e7.	0.6	29
273	Timing of Angiography and Revascularization in Acute Coronary Syndromes: An Analysis of the TACTICS-TIMI-18 Trial. <i>Journal of Interventional Cardiology</i> , 2004, 17, 81-86.	0.5	28
274	Intracoronary bolus administration of eptifibatid during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 47-50.	1.0	28
275	Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. <i>American Heart Journal</i> , 2013, 166, 64-70.	1.2	28
276	A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. <i>Heart</i> , 2013, 99, 1282-1287.	1.2	28
277	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	1.0	28
278	Machine learning to predict venous thrombosis in acutely ill medical patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 230-237.	1.0	28
279	Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 135-145.	1.0	27
280	Association of Impaired Thrombolysis In Myocardial Infarction Myocardial Perfusion Grade With Ventricular Tachycardia and Ventricular Fibrillation Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 51, 546-551.	1.2	27
281	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. <i>Circulation</i> , 2018, 137, 91-94.	1.6	27
282	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
283	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032.	3.0	27
284	Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 177-184.	1.0	26
285	Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatid compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 549-556.	1.2	26
286	Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. <i>American Heart Journal</i> , 2004, 147, 847-852.	1.2	26
287	Association of a History of Systemic Hypertension With Mortality, Thrombotic, and Bleeding Complications Following Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of Clinical Hypertension</i> , 2006, 8, 315-322.	1.0	26
288	Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 43-51.	1.4	26

#	ARTICLE	IF	CITATIONS
289	Relation Between Infarct Size in ST-Segment Elevation Myocardial Infarction Treated Successfully by Percutaneous Coronary Intervention and Left Ventricular Ejection Fraction Three Months After the Infarct. <i>American Journal of Cardiology</i> , 2010, 106, 635-640.	0.7	26
290	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 317-322.	1.0	26
291	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
292	Potential for Drug-Drug Interactions in Patients Taking Analgesics for Mild-to-Moderate Pain and Low-Dose Aspirin for Cardioprotection. <i>American Journal of Cardiology</i> , 2006, 97, 23-29.	0.7	25
293	Association of Prerandomization Anticoagulant Switching With Bleeding in the Setting of Percutaneous Coronary Intervention (A REPLACE-2 Analysis). <i>American Journal of Cardiology</i> , 2007, 99, 1687-1690.	0.7	25
294	Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Tj ETQq0 0 0 rgBT0 Overlock25 Tf 50 5	0.7	25
295	Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 78-83.	0.4	25
296	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2016, 180, 22-28.	1.2	25
297	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	1.2	25
298	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 626-634.	1.1	25
299	Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 339-347.	0.4	25
300	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864.	1.1	25
301	Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1919-1927.	1.2	25
302	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019, 208, 81-90.	1.2	25
303	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1525-1537.	1.2	25
304	Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 233-237.	1.0	24
305	Early Invasive Strategy Improves Outcomes in Patients With Acute Coronary Syndrome With Previous Coronary Artery Bypass Graft Surgery. <i>Critical Pathways in Cardiology</i> , 2006, 5, 167-172.	0.2	24
306	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 241, 87-96.	0.8	24

#	ARTICLE	IF	CITATIONS
307	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144.	1.4	24
308	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	1.4	24
309	Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated With Higher Platelet Counts in Patients With ST-Elevation Myocardial Infarction (Results from CLARITY-TIMI 28). <i>American Journal of Cardiology</i> , 2006, 98, 761-763.	0.7	23
310	Timing of Glycoprotein IIb/IIIa Inhibitor Use and Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (Results from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 61	0.7	23
311	Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population. <i>European Journal of Radiology</i> , 2010, 76, 188-194.	1.2	23
312	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	1.2	23
313	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016, 37, 1122-1130.	1.0	23
314	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018897.	1.6	23
315	Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2006, 151, 25-31.	1.2	22
316	Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 234-242.	1.0	22
317	Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. <i>American Heart Journal</i> , 2013, 166, 723-728.	1.2	22
318	Andexanet Alfa for Factor Xa Inhibitor Reversal. <i>New England Journal of Medicine</i> , 2016, 375, 2498-2500.	13.9	22
319	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.	1.8	22
320	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22
321	The Prognostic Value of Serum Creatinine on Admission in Fibrinolytic-Eligible Patients with Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 167-174.	1.0	21
322	Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 92, 595-597.	0.7	21
323	Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 383-386.	0.7	21
324	Administration of Intracoronary Eptifibatide During ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2005, 96, 1494-1497.	0.7	21

#	ARTICLE	IF	CITATIONS
325	Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2007, 100, 1734-1738.	0.7	21
326	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an EXTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 11-17.	1.0	21
327	Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb/IIIa inhibitors. <i>American Heart Journal</i> , 2009, 158, 416-421.	1.2	21
328	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2017, 244, 59-66.	0.8	21
329	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018, 122, 1459-1464.	0.7	21
330	First Human Use of RUCâ€4: A Nonactivating Secondâ€Generation Smallâ€Molecule Platelet Glycoprotein IIb/IIIa (Integrin Î±IIbÎ²3) Inhibitor Designed for Subcutaneous Pointâ€ofâ€Care Treatment of STâ€Segmentâ€Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e016552.	1.6	21
331	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	1.4	21
332	Minimal ST-segment deviation: A simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. <i>American Heart Journal</i> , 2002, 144, 790-795.	1.2	21
333	Association between short-term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography. <i>American Journal of Cardiology</i> , 2003, 91, 1107-1109.	0.7	20
334	The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. <i>European Heart Journal</i> , 2004, 25, 1139-1145.	1.0	20
335	Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1149-1155.	0.4	20
336	Adjunctive Transcutaneous Ultrasound With Thrombolysis. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 352-359.	1.1	20
337	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016, 181, 92-100.	1.2	20
338	Effect of extendedâ€duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1913-1922.	1.9	20
339	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2022, 145, 97-106.	1.6	20
340	Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. <i>American Heart Journal</i> , 2007, 154, 54-61.	1.2	19
341	Relation Between Myocardial Infarct Size and Ventricular Tachyarrhythmia Among Patients With Preserved Left Ventricular Ejection Fraction Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 104, 475-479.	0.7	19
342	Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSEâ€AMI study. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 704-710.	0.7	19

#	ARTICLE	IF	CITATIONS
343	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.	1.2	19
344	The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 695-702.	0.4	19
345	Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1664-1675.	1.4	19
346	Intracoronary Administration of Abciximab in ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2008, 118, 6-8.	1.6	18
347	Association of Thrombolysis in Myocardial Infarction Myocardial Perfusion Grade with cardiovascular magnetic resonance measures of infarct architecture after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2009, 158, 84-91.	1.2	18
348	Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 927-935.	1.1	18
349	Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. <i>Heart and Vessels</i> , 2014, 29, 15-20.	0.5	18
350	The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 468-474.	0.4	18
351	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 997-1005.	1.9	18
352	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	1.0	18
353	Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). <i>Clinical Cardiology</i> , 2001, 24, 577-584.	0.7	17
354	Quantitative comparison of coronary artery flow and myocardial perfusion in patients with acute myocardial infarction in the presence and absence of recent cocaine use. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 239-245.	1.0	17
355	Safety and efficacy of tenecteplase in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 791-798.	0.9	17
356	Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. <i>European Heart Journal</i> , 2006, 27, 2040-2045.	1.0	17
357	Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 944-952.	1.1	17
358	Usefulness of Monocyte Chemoattractant Protein-1 to Predict No-Reflow and Three-Year Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2013, 112, 187-193.	0.7	17
359	Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). <i>American Journal of Cardiology</i> , 2016, 118, 1097-1104.	0.7	17
360	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	0.7	17

#	ARTICLE	IF	CITATIONS
361	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	1.4	17
362	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019, 45, 477-487.	3.9	17
363	Techniques in the Angiographic Analysis of Coronary Flow: Past, Present, and Future. <i>Journal of Interventional Cardiology</i> , 1996, 9, 429-444.	0.5	16
364	Association of an activated clotting time $\geq 250$ seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). <i>American Journal of Cardiology</i> , 2003, 91, 976-978.	0.7	16
365	Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). <i>American Journal of Cardiology</i> , 2004, 94, 492-494.	0.7	16
366	Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. <i>International Journal of Cardiology</i> , 2013, 167, 2580-2587.	0.8	16
367	Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 350-356.	0.7	16
368	Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy). <i>American Journal of Cardiology</i> , 2015, 115, 1389-1395.	0.7	16
369	The treatment of missing data in a large cardiovascular clinical outcomes study. <i>Clinical Trials</i> , 2016, 13, 344-351.	0.7	16
370	Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 49, 237-243.	0.7	15
371	Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 90, 766-770.	0.7	15
372	Moving Toward Improved Care for the Patient With ST-Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 441-443.	0.9	15
373	Endoscopic Harvesting Device Type and Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. <i>Annals of Surgery</i> , 2014, 260, 402-408.	2.1	15
374	Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb/IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation). <i>American Journal of Cardiology</i> , 2015, 115, 711-715.	0.7	15
375	Impairment of myocardial perfusion in both culprit and nonculprit arteries in acute myocardial infarction: a LIMIT AMI substudy. <i>American Journal of Cardiology</i> , 2003, 91, 325-328.	0.7	14
376	Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 384-393.	1.0	14
377	Effect of Optison on Pulmonary Artery Systolic Pressure and Pulmonary Vascular Resistance. <i>American Journal of Cardiology</i> , 2013, 112, 1657-1661.	0.7	14
378	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003114.	1.4	14

#	ARTICLE	IF	CITATIONS
379	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. <i>American Heart Journal</i> , 2017, 189, 1-8.	1.2	14
380	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 1-8.	1.0	14
381	Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. <i>Journal of the American College of Cardiology</i> , 2005, 45, 357-362.	1.2	13
382	Incremental Benefit of 80-lead Electrocardiogram Body Surface Mapping Over the 12-lead Electrocardiogram in the Detection of Acute Coronary Syndromes in Patients Without ST-segment Elevation Myocardial Infarction: Results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT MI) Trial. <i>Academic Emergency Medicine</i> , 2010, 17, 932-939.	0.8	13
383	Angiographic Validation of the American College of Cardiology Foundationâ€”The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies Study. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 11-18.	1.4	13
384	Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 310-316.	1.0	13
385	Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes After Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2014, 97, 824-830.	0.7	13
386	Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: An analysis of Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI). <i>American Heart Journal</i> , 2015, 169, 86-93.	1.2	13
387	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.	0.7	13
388	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	1.4	13
389	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1434-1446.	1.1	13
390	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2021, 93, 6737-6749.	2.5	13
391	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	1.5	13
392	Evolution of single-lead ECG for STEMI detection using a deep learning approach. <i>International Journal of Cardiology</i> , 2022, 346, 47-52.	0.8	13
393	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. <i>Journal of the American Heart Association</i> , 2022, 11, e024754.	1.6	13
394	Combination Reperfusion Therapy with Eptifibatid and Tenecteplase for Acute Myocardial Infarction. <i>Cardiology</i> , 2001, 1, 5-13.	0.3	12
395	Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial. <i>American Heart Journal</i> , 2005, 150, 79-88.	1.2	12
396	Enoxaparin in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 387-399.	0.6	12

#	ARTICLE	IF	CITATIONS
397	Benefits of pharmacological facilitation with glycoprotein IIb/IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 288-298.	1.0	12
398	Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb/IIIa inhibitors: insights from the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 23-28.	1.0	12
399	Impact of Hypertension on Distal Embolization, Myocardial Perfusion, and Mortality in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. <i>American Journal of Cardiology</i> , 2013, 112, 1083-1086.	0.7	12
400	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	0.7	12
401	Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 129-136.	1.2	12
402	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 983-992.	1.1	12
403	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 186-193.	0.4	12
404	Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). <i>American Journal of Cardiology</i> , 2020, 125, 485-490.	0.7	12
405	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020, 120, 924-936.	1.8	12
406	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1562-1573.	1.8	12
407	Heart Failure. <i>Critical Pathways in Cardiology</i> , 2004, 3, 194-204.	0.2	12
408	Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI iii Registry). <i>American Journal of Cardiology</i> , 2002, 90, 1154-1156.	0.7	11
409	Time for contrast material to traverse the epicardial artery and the myocardium in ST-Segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 91, 1163-1167.	0.7	11
410	Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2006, 151, S24-S29.	1.2	11
411	Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapy Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. <i>American Heart Journal</i> , 2008, 155, 133-139.	1.2	11
412	Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 233-239.	1.0	11
413	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	1.2	11
414	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	0.8	11



#	ARTICLE	IF	CITATIONS
415	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Review of Cardiovascular Therapy, 2017, 15, 237-245.	0.6	11
416	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. Journal of Thrombosis and Thrombolysis, 2017, 44, 457-465.	1.0	11
417	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007124.	1.4	11
418	Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. Journal of Clinical Epidemiology, 2002, 55, 121-128.	2.4	10
419	Intra-aortic balloon pump placement following aorto-iliac angioplasty and stent placement. Catheterization and Cardiovascular Interventions, 2002, 55, 163-168.	0.7	10
420	Association of initial Thrombolysis in Myocardial Infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A National Registry of Myocardial Infarction-5 (NRM-5) analysis. American Heart Journal, 2011, 162, 178-183.	1.2	10
421	Angiographic Outcomes With Early Eptifibatid Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). American Journal of Cardiology, 2014, 113, 1297-1305.	0.7	10
422	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	10
423	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq1 1 0.784314 rgBT /Oven 2017, 120, 904-910.	0.7	10
424	Silent Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 9-11.	1.2	10
425	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2018, 46, 346-350.	1.0	10
426	Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. Atherosclerosis, 2018, 277, 211-218.	0.4	10
427	Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. American Heart Journal, 2018, 203, 17-24.	1.2	10
428	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology, 2018, 270, 96-101.	0.8	10
429	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007342.	1.4	10
430	Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events. Journal of the American College of Cardiology, 2019, 74, 2047-2055.	1.2	10
431	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS-TIMI 51. Journal of the American Heart Association, 2019, 8, .	1.6	10
432	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 96, E102-E109.	0.7	10

#	ARTICLE	IF	CITATIONS
433	Comparison of errors in estimating weight and in dosing of single-bolus Tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). American Journal of Cardiology, 2002, 90, 51-54.	0.7	9
434	Predicting Irreversible Left Ventricular Dysfunction After Acute Myocardial Infarction. American Journal of Cardiology, 2009, 103, 1206-1209.	0.7	9
435	Transfusion associated microchimerism: a heretofore little recognized complication following transfusion. Journal of Thrombosis and Thrombolysis, 2009, 27, 57-67.	1.0	9
436	Relation of Circulating Osteoprotegerin Levels on Admission to Microvascular Obstruction After Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 857-862.	0.7	9
437	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 227-232.	1.0	9
438	The Democratization of Medical Research and Education Through Social Media. JAMA Cardiology, 2017, 2, 9.	3.0	9
439	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 2017, 117, 1093-1100.	1.8	9
440	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 680.	3.0	9
441	Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2001, 53, 6-11.	0.7	8
442	Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial. Journal of Thrombosis and Thrombolysis, 2006, 22, 13-21.	1.0	8
443	Reperfusion strategies for ST-elevation myocardial infarction. Current Cardiology Reports, 2007, 9, 281-288.	1.3	8
444	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). American Journal of Cardiology, 2016, 118, 625-631.	0.7	8
445	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. Catheterization and Cardiovascular Interventions, 2016, 87, 391-400.	0.7	8
446	Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharmaceutical Statistics, 2017, 16, 445-450.	0.7	8
447	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH Open, 2018, 02, e16-e24.	0.7	8
448	Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial). American Journal of Cardiology, 2019, 123, 571-575.	0.7	8
449	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.	1.6	8
450	VE-1902: A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. Thrombosis Research, 2020, 190, 112-121.	0.8	8

#	ARTICLE	IF	CITATIONS
451	Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. <i>American Heart Journal</i> , 2022, 249, 86-97.	1.2	8
452	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. <i>Current Atherosclerosis Reports</i> , 2022, 24, 585-597.	2.0	8
453	Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 1113-1117.	0.7	7
454	Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 1537-1539.	0.7	7
455	C-Reactive Protein and Cardiovascular Outcomes in Smokers Versus Nonsmokers in Non-ST-Elevation Acute Coronary Syndrome (from the TACTICS-TIMI 18 Trial). <i>American Journal of Cardiology</i> , 2005, 96, 635-638.	0.7	7
456	Impact of Saphenous Vein Graft Radiographic Markers on Clinical Events and Angiographic Parameters. <i>Annals of Thoracic Surgery</i> , 2008, 85, 520-524.	0.7	7
457	Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 253-258.	1.0	7
458	Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 493-500.	1.0	7
459	Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 363-373.	0.7	7
460	Going Polymer Free and Dual Antiplatelet Free Earlier. <i>Journal of the American College of Cardiology</i> , 2017, 69, 172-175.	1.2	7
461	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	7
462	Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy – Real World Experience. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 531-536.	1.6	7
463	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	0.4	7
464	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019, 139, 1234-1236.	1.6	7
465	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.	0.9	7
466	Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). <i>American Journal of Cardiology</i> , 2020, 125, 661-669.	0.7	7
467	Coronary artery injection technique: A quantitative in vivo investigation using modern catheters. , 1998, 44, 34-39.		6
468	Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 13, 9-12.	1.0	6

#	ARTICLE	IF	CITATIONS
469	Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1170-1176.	1.2	6
470	Relation of Hyperemic Epicardial Flow to Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy. <i>American Journal of Cardiology</i> , 2008, 101, 1232-1238.	0.7	6
471	“Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2385-2387.	1.2	6
472	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. <i>JAMA Cardiology</i> , 2017, 2, 673.	3.0	6
473	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	6
474	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018, 197, 1-8.	1.2	6
475	Most Promising Therapies in Interventional Cardiology. <i>Current Cardiology Reports</i> , 2019, 21, 26.	1.3	6
476	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019, 123, 355-360.	0.7	6
477	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019, 278, 217-222.	0.8	6
478	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.	1.0	6
479	Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. <i>American Heart Journal</i> , 2020, 228, 91-97.	1.2	6
480	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	1.1	6
481	Digital technologies and the democratization of clinical research: Social media, wearables, and artificial intelligence. <i>Contemporary Clinical Trials</i> , 2022, 117, 106767.	0.8	6
482	Use of Reperfusion Therapies in Elderly Patients with Acute Myocardial Infarction. <i>Drugs and Aging</i> , 2001, 18, 587-596.	1.3	5
483	Angiographic and clinical characteristics associated with the development of q-wave and non-q-wave myocardial infarction in the thrombolysis in myocardial infarction (timi) 14 trial. <i>American Heart Journal</i> , 2003, 146, 42-47.	1.2	5
484	Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 108-111.	0.7	5
485	Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2005, 95, 337-342.	0.7	5
486	Antiplatelet Therapy: Anti-Ischemic Benefits versus Bleeding Risk. <i>Journal of Interventional Cardiology</i> , 2008, 21, S3-9.	0.5	5

#	ARTICLE	IF	CITATIONS
487	Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 10-13.	1.0	5
488	Optimal selection of STEMI treatment strategies in the current era. <i>Current Opinion in Cardiology</i> , 2012, 27, 651-654.	0.8	5
489	Design and rationale of the ANALYZE ST study: A prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. <i>American Heart Journal</i> , 2014, 168, 424-429.e1.	1.2	5
490	Effect of Cocaine on Coronary Microvasculature. <i>Journal of the American College of Cardiology</i> , 2018, 71, 954-955.	1.2	5
491	Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 524-530.	1.6	5
492	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E348-E355.	0.7	5
493	Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	0.8	5
494	Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 845-855.	0.6	5
495	Moving From Hope to Hard Work in Data Sharing. <i>JAMA Cardiology</i> , 2018, 3, 795.	3.0	5
496	Net clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.	1.9	5
497	Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 567-576.	0.7	5
498	Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 93-104.	1.0	5
499	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
500	Door-to-balloon delays with PCI in acute myocardial infarction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 69-77.	0.4	4
501	Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 228-233.	0.7	4
502	The association of impaired myocardial perfusion and monocytosis with late recovery of left ventricular function following primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2006, 27, 2487-2488.	1.0	4
503	Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 106-112.	1.0	4
504	The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008, 131, 105-112.	0.8	4

#	ARTICLE	IF	CITATIONS
505	Timing and Duration of Myocardial Ischemia on Holter Monitoring Following Percutaneous Coronary Intervention and Their Association With Clinical Outcomes (a PROTECT-TIMI 30 Substudy Analysis). <i>American Journal of Cardiology</i> , 2009, 104, 36-40.	0.7	4
506	Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 889-900.	1.5	4
507	Clinical Implications and Correlates of Q Waves in Patients With <scp>ST</scp>-Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the <scp>CLARITYâ€TIMI</scp> 28 Trial. <i>Clinical Cardiology</i> , 2014, 37, 160-166.	0.7	4
508	Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1048-1049.	1.2	4
509	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	0.7	4
510	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120010390.	1.4	4
511	The Open Artery Hypothesis: Past, Present, and Future. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 101-112.	1.0	3
512	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2013, 24, 321-327.	0.3	3
513	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". <i>Circulation</i> , 2015, 132, e29.	1.6	3
514	Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, e50.	13.9	3
515	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 195, 128-135.	0.8	3
516	Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 421-429.	1.0	3
517	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. <i>Clinical Cardiology</i> , 2022, , .	0.7	3
518	Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 224-227.	0.7	2
519	Impact of Iodinated Contrast Injections on Percent Diameter Coronary Arterial Stenosis and Implications for Trials of Intracoronary Pharmacotherapies in Patients With ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2007, 100, 13-17.	0.7	2
520	Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes. <i>American Journal of Emergency Medicine</i> , 2009, 27, 595-606.	0.7	2
521	Fractional Flow Reserve. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1282-1283.	1.1	2
522	Percutaneous Coronary Interventions in Facilities Without Cardiac Surgery on Site. <i>Current Cardiology Reports</i> , 2011, 13, 432-438.	1.3	2

#	ARTICLE	IF	CITATIONS
523	Intracoronary delivery of eptifibatid with the ClearWay® RX infusion catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 222-227.	0.7	2
524	Patients with Tombstoning Pattern on the Admission Electrocardiography Who Have Undergone Primary Percutaneous Coronary Intervention for Anterior Wall ST-Elevation Myocardial Infarction: In-Hospital and Midterm Clinical Outcomes. <i>Annals of Noninvasive Electrocardiology</i> , 2012, 17, 315-322.	0.5	2
525	Bioresorbable Vascular Scaffolds in Daily Clinical Practice. <i>Journal of the American College of Cardiology</i> , 2015, 65, 802-804.	1.2	2
526	Prevention of Bleeding in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 376, 993-994.	13.9	2
527	Collateral Circulation in Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 915-917.	1.1	2
528	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017, 188, 147-155.	1.2	2
529	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711.	1.8	2
530	Independence of clinical events committees: A consensus statement from clinical research organizations. <i>American Heart Journal</i> , 2022, 248, 120-129.	1.2	2
531	Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 7, 287-302.	1.0	1
532	The relationship of intracoronary stent placement following thrombolytic therapy to tissue level perfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 13, 63-68.	1.0	1
533	Efficacy and Safety of Edifoligide—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1513.	3.8	1
534	Underestimation of the effect of bleeding in clinical trials — Authors' reply. <i>Lancet, The</i> , 2009, 374, 1145-1146.	6.3	1
535	Myocardial Infarct Size Reduction With Pexelizumab. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 61-63.	2.3	1
536	Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 448-452.	1.0	1
537	Response to Letter Regarding Article, "Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non-ST-Segment Elevation Acute Coronary Syndromes". <i>Circulation</i> , 2013, 127, e634.	1.6	1
538	Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". <i>Circulation</i> , 2016, 133, e665.	1.6	1
539	Logistical Challenges Associated With Implementing Precision Medicine—Reply. <i>JAMA Cardiology</i> , 2019, 4, 1301.	3.0	1
540	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	0.7	1

#	ARTICLE	IF	CITATIONS
541	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008160.	1.4	1
542	&lt;p&gt;The AngelMed GuardianÂ® System in the Detection of Coronary Artery Occlusion: Current Perspectives&lt;/p&gt;. <i>Medical Devices: Evidence and Research</i> , 2020, Volume 13, 1-12.	0.4	1
543	Dual Antiplatelet Therapy Following PCI for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2447-2449.	1.2	1
544	Prognosis of Claimsâ€•Versus Trialâ€•Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. <i>Journal of the American Heart Association</i> , 2021, 10, e018744.	1.6	1
545	Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	1
546	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. <i>Thrombosis Research</i> , 2022, 211, 63-69.	0.8	1
547	Key references on a wide variety of topics pertaining to coronary artery blood flow and patency. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 85-93.	1.0	0
548	Confusion in reperfusion**Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1186-1187.	1.2	0
549	Greater Benefit of Early Invasive Strategy for Unstable Angina and Non-ST Elevation Myocardial Infarction in United States Compared With Non-United States Patients. <i>Critical Pathways in Cardiology</i> , 2004, 3, 95-100.	0.2	0
550	Current assessments of the adequacy of myocardial perfusion during acute MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 25-34.	0.4	0
551	Advances in antithrombin and antiplatelet therapy for percutaneous coronary intervention. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 284-289.	0.8	0
552	Introduction. <i>Journal of Interventional Cardiology</i> , 2008, 21, S1-S2.	0.5	0
553	Intensive statin therapy: a goal worth targeting. <i>Interventional Cardiology</i> , 2010, 2, 103-105.	0.0	0
554	Newer Pharmaceutical Agents for STEMI Interventions. <i>Interventional Cardiology Clinics</i> , 2012, 1, 429-440.	0.2	0
555	TCT-58 Effects of Mechanical Thrombectomy and Intracoronary Abciximab on Coronary Flow and Infarct Size During Primary PCI: Analysis from the INFUSE-AMI Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, B18.	1.2	0
556	TCT-486 Relationship Between White Blood Cell Count and Final Infarct Size in Patients with ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Analysis from the INFUSE-AMI Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, B140.	1.2	0
557	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After Stent Implantation. <i>Interventional Cardiology Clinics</i> , 2013, 2, 595-606.	0.2	0
558	Advances in understanding percutaneous coronary intervention pharmacology. <i>Coronary Artery Disease</i> , 2014, 25, 453-455.	0.3	0



#	ARTICLE	IF	CITATIONS
559	CLOPIDOGREL WITH AND WITHOUT PROTON PUMP INHIBITOR USE: A PARIS REGISTRY ANALYSIS. Journal of the American College of Cardiology, 2014, 63, A1817.	1.2	0
560	TCT-238 Impact of Smoking on Infarct Size and Adverse Events in Patients With Anterior ST-Elevation Myocardial Infarction: Results From the INFUSE-AMI Trial. Journal of the American College of Cardiology, 2015, 66, B92-B93.	1.2	0
561	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	0
562	IMPACT OF PRIOR CEREBROVASCULAR EVENTS ON ISCHEMIC AND BLEEDING OUTCOMES WITH CANGRELOR IN PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2016, 67, 198.	1.2	0
563	Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy". Circulation, 2017, 136, 117-117.	1.6	0
564	TCT-724 Impact of Coronary Calcification Severity on Clinical Outcomes After Contemporary PCI " Insights From the CHAMPION PHOENIX Trial. Journal of the American College of Cardiology, 2017, 70, B308-B309.	1.2	0
565	The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease " Where Is the Moon Now?. Progress in Cardiovascular Diseases, 2018, 60, 457-459.	1.6	0
566	SECURE PCI: how important can a subgroup analysis be?. Journal of Thoracic Disease, 2018, 10, S2032-S2034.	0.6	0
567	Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy. Journal of the American College of Cardiology, 2018, 72, 1801-1803.	1.2	0
568	Reply. JACC: Cardiovascular Interventions, 2018, 11, 1539-1540.	1.1	0
569	TCT-518 Utility of Troponin and Creatine Kinase in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Clinical Outcomes After Acute Anterior Myocardial Infarction: The INFUSE-AMI Trial. Journal of the American College of Cardiology, 2019, 74, B512.	1.2	0
570	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y 12 Inhibitor Pretreatment. Circulation: Cardiovascular Interventions, 2019, 12, e007445.	1.4	0
571	Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis. The Cochrane Library, 2020, , .	1.5	0
572	The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq0 0 0 rgBT /Overlock 10 T 3824-3824.	0.6	0
573	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e29-e30.	1.4	0
574	Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 470.	0.5	0
575	Acute ST Segment Elevation Myocardial Infarction. , 0, , 216-239.		0